Spyre Therapeutics, Inc (SYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spyre Therapeutics, Inc. faces significant challenges following its transition from a ‘smaller reporting company’ status, effective January 1, 2025. This shift subjects the company to enhanced disclosure and compliance requirements, including auditor attestation mandates and detailed executive compensation disclosures. The resultant increase in legal and compliance costs may divert management’s focus from core business operations, potentially affecting stock market performance and risking regulatory sanctions if compliance is delayed. The company must adapt to these new obligations by March 31, 2025, and will reassess its filer status by June 30, 2025, to maintain compliance and mitigate financial risks.
The average SYRE stock price target is $64.00, implying 224.87% upside potential.
To learn more about Spyre Therapeutics, Inc’s risk factors, click here.